Top

Published in:

01-05-2020 | Liver Transplantation | Review Article

Liver transplantation for non-resectable colorectal liver metastasis: where we are and where we are going

Authors: Juan Glinka, Victoria Ardiles, Juan Pekolj, Juan Mattera, Rodrigo Sanchez Clariá, Eduardo de Santibañes, Martin de Santibañes

Published in: Langenbeck's Archives of Surgery | Issue 3/2020

Abstract

Purpose

Almost 50% of patients diagnosed with colorectal cancer (CRC) will develop liver metastasis (LM). Although their only long-term curative treatment is surgery, less than half of these patients can be eventually resected. Therefore, palliative chemotherapy is offered as a definitive option, though with poor results. Recently, the University of Oslo group has published encouraging results in the treatment of these patients with liver transplantation (LT), whereby worldwide interest in this option has been renewed.

Methods

A literature review of LT for patients with unresectable colorectal metastasis was performed. This included information regarding patient selection, complications, overall survival (OS) and disease-free survival (DFS), immunosuppression, chemotherapy, and description of the ongoing trials.

Results

Improvements in OS and DFS have been observed in consecutive published prospective trials, as patient selection has been refined. Papers reporting OS of patients who randomly presented similar selection criteria also exhibited good results.

Conclusion

LT within the available therapeutic options in patients with CRC-LM seems to be a compelling alternative in carefully selected patients. The ongoing trials will provide valuable information regarding selection criteria, immunosuppressive therapy and different modalities of adjuvant chemotherapy, which are, to our knowledge, the vital platform of LT in CRC-LM. Although some of the developing techniques involve living donors, graft availability for these patients remains a matter of major concern.

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014 [internet]. CA Cancer J Clin 9–29. https://doi.org/10.3322/caac.21208

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386CrossRef

Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:715–722 discussion 722–4CrossRef

Quan D, Gallinger S, Nhan C, Auer RA, Biagi JJ, Fletcher GG et al (2012) The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: A systematic review [Internet]. Surgery 860–870. https://doi.org/10.1016/j.surg.2011.12.018

House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP et al (2010) Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 210:744–752 752–5CrossRef

Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien C-R, Makhson A et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417CrossRef

Adam R, Karam V, Delvart V, O’Grady J, Mirza D, Klempnauer J et al (2012) Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR) [Internet]. J Hepatol 675–688. https://doi.org/10.1016/j.jhep.2012.04.015

Mühlbacher F, Huk I, Steininger R, Gnant M, Götzinger P, Wamser P et al (1991) Is orthotopic liver transplantation a feasible treatment for secondary cancer of the liver? Transplant Proc 23:1567–1568PubMed

Hagness M, Foss A, Line P-D, Scholz T, Jørgensen PF, Fosby B, Boberg KM, Mathisen Ø, Gladhaug IP, Egge TS, Solberg S, Hausken J, Dueland S (2013) Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 257:800–806CrossRef

10.

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al (1996) Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis [Internet]. N Engl J Med 693–700. https://doi.org/10.1056/nejm199603143341104

11.

Sapisochin G, Bruix J (2017) Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol 14:203–217CrossRef

12.

Hibi T, Itano O, Shinoda M, Kitagawa Y (2017) Liver transplantation for hepatobiliary malignancies: a new era of “transplant oncology” has begun. Surg Today 47:403–415CrossRef

13.

Rosen CB, Heimbach JK, Gores GJ (2008) Surgery for cholangiocarcinoma: the role of liver transplantation [Internet]. HPB 186–189. https://doi.org/10.1080/13651820801992542

14.

Jadlowiec CC, Rosen CB. Transplantation for hilar cholangiocarcinoma [Internet]. Case-Based Lessons in the Management of Complex Hepato-Pancreato-Biliary Surgery. 2017. pp. 259–273. https://doi.org/10.1007/978-3-319-50868-9_20

15.

Hoti E, Adam R (2008) Liver transplantation for primary and metastatic liver cancers [Internet]. Transpl Int 1107–1117. https://doi.org/10.1111/j.1432-2277.2008.00735.x

16.

Lucas AS, O’Neil BH, Goldberg RM (2011) A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer [Internet]. Clin Colorectal Cancer 238–244. https://doi.org/10.1016/j.clcc.2011.06.012

17.

Toso C, Marques HP, Andres A, Castro Sousa F, Adam R, Kalil A et al (2017) Liver transplantation for colorectal liver metastasis: survival without recurrence can be achieved [Internet]. Liver Transpl 1073–1076. https://doi.org/10.1002/lt.24791

18.

Uskudar O, Raja K, Schiano TD, Fiel MI, del Rio Martin J, Chang C. Liver Transplantation Is Possible in Some Patients with Liver Metastasis of Colon Cancer [Internet]. Transplantation Proceedings. 2011. pp. 2070–2074. https://doi.org/10.1016/j.transproceed.2011.03.052

19.

Grut H, Revheim M-E, Line P-D, Dueland S (2018) Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation. Nucl Med Commun 39:621–627CrossRef

20.

Xia Q, Liu J, Wu C, Song S, Tong L, Huang G, Feng Y, Jiang Y, Liu Y, Yin T, Ni Y (2015) Prognostic significance of 18FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis [internet]. Cancer Imaging 15:19. https://doi.org/10.1186/s40644-015-0055-z CrossRefPubMedPubMedCentral

21.

Grut H, Dueland S, Line PD, Revheim ME (2018) The prognostic value of 18F–FDG PET/CT prior to liver transplantation for nonresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging 45:218–225CrossRef

22.

Dueland S, Syversveen T, Solheim JM, Solberg S, Grut H, Bjørnbeth BA, Hagness M, Line PD (2019) Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases. Ann Surg 271:212–218. https://doi.org/10.1097/SLA.0000000000003404 CrossRef

23.

Kappel S, Kandioler D, Steininger R, Längle F, Wrba F, Ploder M et al (2006) Genetic detection of lymph node micrometastases: a selection criterion for liver transplantation in patients with liver metastases after colorectal cancer [Internet]. Transplantation 64–70. https://doi.org/10.1097/01.tp.0000189711.98971.9c

24.

Bjørnelv GMW, Dueland S, Line PD, Joranger P, Fretland ÅA, Edwin B et al (2019) Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver [Internet]. Br J Surg 132–141. https://doi.org/10.1002/bjs.10962

25.

Dueland S, Line P-D, Hagness M, Foss A, Andersen MH (2019) Long-term quality of life after liver transplantation for non-resectable colorectal metastases confined to the liver. BJS Open 3:180–185CrossRef

26.

Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRef

27.

Tector AJ, Mangus RS, Chestovich P, Vianna R, Fridell JA, Milgrom ML, Sanders C, Kwo PY (2006) Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg 244:439–450PubMedPubMedCentral

28.

McCormack L, Dutkowski P, El-Badry AM, Clavien P-A (2011) Liver transplantation using fatty livers: always feasible? J Hepatol 54:1055–1062CrossRef

29.

Borchert D, Glanemann M, Mogl M, Langrehr JM, Neuhaus P (2005) Older liver graft transplantation, cholestasis and synthetic graft function. Transpl Int 18:709–715CrossRef

30.

Hagness M, Foss A, Egge TS, Dueland S (2014) Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer [Internet]. Ann Surg Oncol 1323–1329. https://doi.org/10.1245/s10434-013-3449-9

31.

Dueland S, Guren TK, Hagness M, Glimelius B, Line P-D, Pfeiffer P, Foss A, Tveit KM (2015) Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer? Ann Surg 261:956–960CrossRef

32.

Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, Salvatore L, Cremolini C, Stasi I, Brunetti I, Fabbri MA, Puglisi M, Trenta P, Granetto C, Chiara S, Fioretto L, Allegrini G, Crino L, Andreuccetti M, Falcone A (2011) Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 103:21–30CrossRef

33.

Line P-D, Hagness M, Dueland S (2018) The potential role of liver transplantation as a treatment option in colorectal liver metastases. Can J Gastroenterol Hepatol 2018:8547940CrossRef

34.

Samuel D, Colombo M, El-Serag H, Sobesky R, Heaton N (2011) Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma [Internet]. Liver Transpl S6–S13. https://doi.org/10.1002/lt.22423

35.

Olthoff KM, Forner A, Hübscher S, Fung J (2011) What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation? [Internet]. Liver Transpl S26–S33. https://doi.org/10.1002/lt.22352

36.

Hrehoreţ D, Alexandrescu S, Braşoveanu V, Grigorie R, Zielinski C, Popescu I (2013) Liver transplantation in a patient with unresectable colorectal liver metastases -- a case report. Chirurgia 108:719–724PubMed

37.

Rauchfuß F, Nadalin S, Königsrainer A, Settmacher U (2019) Living donor liver transplantation with two-stage hepatectomy for patients with isolated, irresectable colorectal liver-the LIVER-T(W)O-HEAL study. World J Surg Oncol 17:11CrossRef

38.

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L (2016) RECIST 1.1—update and clarification: from the RECIST committee. Eur J Cancer 62:132–137CrossRef

39.

Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S et al (2012) Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII Study [Internet]. J Clin Oncol 1755–1762. https://doi.org/10.1200/jco.2011.38.0915

40.

Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R (2015) Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 26:702–708CrossRef

41.

Lv W, Zhang GQ, Jiao A, Zhao BC, Shi Y, Chen BM et al (2017) Chemotherapy plus Cetuximab versus chemotherapy alone for patients with KRAS wild type unresectable liver-confined metastases colorectal cancer: an updated meta-analysis of RCTs. Gastroenterol Res Pract 2017:8464905PubMedPubMedCentral

42.

Passot G, Soubrane O, Giuliante F, Zimmitti G, Goéré D, Yamashita S et al (2017) Recent advances in chemotherapy and surgery for colorectal liver metastases [Internet]. Liver Cancer 72–79. https://doi.org/10.1159/000449349

43.

Tan H-H, Fiel MI, del Rio MJ, Schiano TD (2009) Graft rejection occurring in post-liver transplant patients receiving cytotoxic chemotherapy: a case series. Liver Transpl 15:634–639CrossRef

44.

Smedman TM, Line P-D, Guren TK, Dueland S (2018) Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients. Acta Oncol 57:1414–1418CrossRef

45.

Dueland S, Guren TK, Boberg KM, Reims HM, Grzyb K, Aamdal S, Julsrud L, Line PD (2017) Acute liver graft rejection after ipilimumab therapy. Ann Oncol 28:2619–2620CrossRef

46.

Smedman TM, Guren TK, Line P-D, Dueland S (2019) Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation - a retrospective study. Transpl Int 32:1144–1150. https://doi.org/10.1111/tri.13471 CrossRefPubMed

47.

Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP et al (2008) EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer [Internet]. J Clin Oncol 2311–2319. https://doi.org/10.1200/jco.2007.13.1193

48.

Geissler EK, Schlitt HJ (2009) Immunosuppression for liver transplantation. Gut. 58:452–463CrossRef

49.

Piselli P, Serraino D, Segoloni GP, Sandrini S, Piredda GB, Scolari MP, Rigotti P, Busnach G, Messa P, Donati D, Schena FP, Maresca MC, Tisone G, Veroux M, Sparacino V, Pisani F, Citterio F, Immunosuppression and Cancer Study Group (2013) Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009. Eur J Cancer 49:336–344CrossRef

50.

Mukthinuthalapati PK, Gotur R, Ghabril M (2016) Incidence, risk factors and outcomes of de novo malignancies post liver transplantation. World J Hepatol 8:533–544CrossRef

51.

Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715–727CrossRef

52.

Toso C, Merani S, Bigam DL, Shapiro AMJ, Kneteman NM (2010) Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology. 51:1237–1243CrossRef

53.

Rupertus K, Dahlem C, Menger MD, Schilling MK, Kollmar O (2009) Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation [Internet]. Ann Surg Oncol 2629–2637. https://doi.org/10.1245/s10434-009-0564-8

54.

Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128–135CrossRef

55.

Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, Line PD, Dueland S (2018) Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. Br J Surg 105:295–301CrossRef

56.

Liver transplantation compared to chemotherapy in patients with colorectal cancer - full text view - ClinicalTrials.gov [Internet]. [cited 17 Jul 2019]. Available: https://clinicaltrials.gov/ct2/show/NCT03494946

57.

Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goralcyk A, Hörbelt R, Kroemer A, Loss M, Rümmele P, Scherer MN, Padberg W, Königsrainer A, Lang H, Obed A, Schlitt HJ (2012) Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 255:405–414CrossRef

58.

Terpstra OT, Schalm SW, Weimar W, Willemse PJ, Baumgartner D, Groenland TH et al (1988) Auxiliary partial liver transplantation for end-stage chronic liver disease. N Engl J Med 319:1507–1511CrossRef

59.

Line P-D, Hagness M, Solheim JM, Dueland S (2016) A novel technique for partial liver transplantation and two stage hepatectomy in non-resectable malignant tumors of the liver: the RAPID concept. HPB . Elsevier 18:e14CrossRef

60.

Partial Liver Segment 2/3 Transplantation Study - Full Text View - ClinicalTrials.gov [Internet]. [cited 17 Jul 2019]. Available: https://clinicaltrials.gov/ct2/show/NCT02215889

61.

Liver transplantation in patients with unresectable colorectal liver metastases treated by chemotherapy - full text view - ClinicalTrials.gov [Internet]. [cited 17 Jul 2019]. Available: https://clinicaltrials.gov/ct2/show/NCT02597348

62.

Living donor liver transplantation for unresectable colorectal cancer liver metastases - full text view - ClinicalTrials.gov [Internet]. [cited 17 Jul 2019]. Available: https://clinicaltrials.gov/ct2/show/NCT02864485

63.

Miller CM, Durand F, Heimbach JK, Kim-Schluger L, Lee S-G, Lerut J et al (2016) The international liver transplant society guideline on living liver donation [Internet]. Transplantation 1238–1243. https://doi.org/10.1097/tp.0000000000001247

Title: Liver transplantation for non-resectable colorectal liver metastasis: where we are and where we are going
Authors: Juan Glinka
Victoria Ardiles
Juan Pekolj
Juan Mattera
Rodrigo Sanchez Clariá
Eduardo de Santibañes
Martin de Santibañes
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keywords: Liver Transplantation
Metastasis
Liver Transplantation
Liver Transplantation
Liver Transplantation
Liver Transplantation
Colorectal Cancer
Colorectal Cancer
Cytostatic Therapy
Published in: Langenbeck's Archives of Surgery / Issue 3/2020
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-020-01883-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Liver transplantation for non-resectable colorectal liver metastasis: where we are and where we are going

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

Intraoperative radiotherapy for resectable advanced lower rectal cancer—final results of a randomized controlled trial (UMIN000021353)

Gastrointestinal cancer surgery and enhanced recovery after surgery (ERAS) during COVID-19 outbreak

Patients’ refusal as major limitation of early discharge after colorectal resection in an enhanced recovery program

Non-cross-linked biological mesh in complex abdominal wall hernia: a cohort study

Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus

Surgery in times of COVID-19—recommendations for hospital and patient management